Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Phase 1 study of ABBV-291 in relapsed/refractory B-cell non-Hodgkin lymphoma
jRCT2031240695Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ABBV-291 in B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 7 more, sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability of ABBV-291. Started Feb 2025; status: active, not recruiting.
02
Drugs
ABBV-291
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2031240695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240695.